即用型多分支与医师改良支架的中期结局比较:系统综述与荟萃分析
结果显示两组1年及2年再干预率和死亡率无显著差异,OTSD技术成功率略高但脊髓缺血发生率更高。
要点
- OTSD与PMEG的中期再干预率和死亡率相当。
- OTSD技术成功率略高(98% vs 96%)。
- OTSD脊髓缺血发生率更高(6% vs 0%)。
核心结论
- PMEG与OTSD均展现可接受的中期结局,但比较结果受队列间动脉瘤范围、症状性/破裂表现及随访时长差异限制。
- 两者均为可行策略,器械选择应基于个体解剖、紧急程度和机构经验。
研究设计与样本
- 系统检索MEDLINE、Embase、Scopus和ClinicalTrials.gov截至2025年1月1日。
- 纳入报告PMEG或OTSD修复CAAA或TAAA后1年或2年死亡率或再干预且样本量≥10例的研究。
主要发现
- 1年再干预率PMEG为11%,OTSD为12%(P = .966)。
- 2年再干预率PMEG为15%,OTSD为13%(P = .820)。
- 1年死亡率PMEG为9%,OTSD为8%(P = .714);2年死亡率PMEG为11%,OTSD为12%(P = .758)。
- 技术成功率OTSD略高(98% vs 96%,P = .03),脊髓缺血OTSD更常见(6% vs 0%,P < .0001)。
- 30天死亡率PMEG为1%,OTSD为2%(P = .836);按表现和动脉瘤范围亚组分析主要结局无差异。
临床怎么用
- 对于症状性或破裂的复杂腹主动脉及胸腹主动脉瘤,OTSD和PMEG均可作为紧急修复的可行选择。
- 器械选择需综合考虑患者解剖条件、紧急程度及机构技术专长。
- OTSD需警惕脊髓缺血风险,PMEG需关注技术成功率略低的可能性。
局限性
- 比较结果受队列间动脉瘤范围、症状性/破裂表现及随访时长显著差异的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Custom-manufactured fenestrated-branched endovascular aortic repair devices have demonstrated excellent outcomes for elective repair of complex abdominal (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs). However, for symptomatic or ruptured aneurysms, the manufacturing and shipping time render this option impractical for urgent or emergent repair. To address this clinical need, alternative technologies have been developed, including physician-modified endografts (PMEGs) and off-the-shelf multibranched devices (OTSDs). In this systematic review and meta-analysis, we compare midterm outcomes between OTSDs and PMEGs. DESIGN/METHOD: A systematic search was conducted using the MEDLINE, Embase, Scopus, and ClinicalTrials.gov databases through January 1, 2025. Studies with 10 or more patients reporting 1- or 2-year mortality or reintervention after PMEG or OTSD repair of CAAAs or TAAAs were included. Primary outcomes included midterm reintervention and mortality. Secondary outcomes included 30-day mortality, spinal cord ischemia (SCI), and technical success. Subgroup analyses by presentation and aneurysm extent were also performed. RESULTS: Eighteen studies (11 PMEG, 7 OTSD), including 994 patients (538 PMEGs, 456 OTSDs), were included in the review. One-year reintervention was 11% for PMEG and 12% for OTSD (P = .966), and 2-year reintervention was 15% for PMEG and 13% for OTSD (P = .820). One-year mortality was 9% for PMEG and 8% for OTSD (P = .714), and 2-year mortality was 11% for PMEG and 12% for OTSD (P = .758). Technical success was slightly higher with OTSD (98% vs 96%, P = .03), and SCI occurred more frequently with OTSD (6% vs 0%, P < .0001). Thirty-day mortality was 1% for PMEG and 2% for OTSD (P = .836). Subgroup analyses by presentation and aneurysm extent revealed no differences in primary outcomes. CONCLUSIONS: PMEGs and OTSDs demonstrate acceptable midterm outcomes. However, interpretation of comparative results is limited by substantial differences in aneurysm extent, symptomatic or ruptured presentation, and follow-up duration between the cohorts. Both remain viable strategies, with device selection guided by individual anatomy, urgency, and institutional expertise.
引用
- Han K, Mo H, Guha S, et al. Midterm outcomes of off-the-shelf multibranched versus physician-modified endografts for endovascular repair of complex and thoracoabdominal aortic aneurysms: A systematic review and meta-analysis. J Vasc Surg. 2026. PMID: 41967732. doi:10.1016/j.jvs.2026.03.616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。